We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Devicemakers need to design products that will work in the high-tech hospital environment of the future, experts said at a conference earlier this month.
Novartis is taking advantage of China’s inexpensive labor and rapidly growing drug market by building a $100 million research and development center in Shanghai, the company announced.
Eli Lilly, Pfizer and Bristol-Myers Squibb (BMS) have joined AstraZeneca as targets of subpoenas from the California Office of the Attorney General over marketing practices for top-selling antipsychotic drugs.
The FTC has given Watson Pharmaceuticals permission to buy Andrx as long as the two sell off certain assets, including Andrx’s portfolio of oral contraceptives.
A group of medical officials in Washington state has created a proposal that suggests a maximum daily dosage of narcotic painkillers in an attempt to prevent accidental deaths from overdose.
There is a large gap between public health policy and the scientific evidence for influenza vaccines, and the government programs should be reevaluated due to the amount of resources involved in flu preparedness, according to a recent medical journal article.
AstraZeneca is stopping any further work on an investigative drug for the neurological damage caused by strokes, after it failed to show any effect compared with placebo in a Phase III clinical trial.
The growing use of internet advertising benefits smaller pharmaceutical companies that lack the resources to compete using more traditional methods to market their products, industry observers say.